GenFleet Therapeutics (Shanghai) Inc. (GENFLEET-B, stock code: 02595) published its monthly return for the period ended 28 February 2026, detailing the status of both its Hong Kong-listed and unlisted ordinary shares. Company records indicate that there were no changes to the total number of issued H shares and unlisted shares during the reporting month.

The H share count remained at 338,029,020 shares, representing RMB 33.80 million in issued share capital based on a par value of RMB 0.1 per share. Unlisted shares stood at 32,337,610 shares, totaling RMB 3.23 million in issued share capital. The aggregate issued share capital at month-end was RMB 37.04 million. No share repurchases, conversions, or cancellations were reported.

Public float requirements under the relevant Main Board Rules continued to be met, with GenFleet Therapeutics (Shanghai) Inc. maintaining a float threshold of 19.86%. The company confirmed compliance based on publicly available information. No new share options, warrants, or convertible securities were disclosed for February 2026.